This announcement is a separate document:
康泰生物：关于四价流感病毒裂解疫苗（6-35月龄人群）获得药物临床试验批准通知书的公告
Shenzhen Kangtai Biological Products: Announcement on the approval of drug clinical trial approval for quadrivalent influenza virus split vaccine (6-35 month population).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.